418 related articles for article (PubMed ID: 29074410)
1. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L
Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410
[TBL] [Abstract][Full Text] [Related]
2. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.
Mathers BM; Degenhardt L; Ali H; Wiessing L; Hickman M; Mattick RP; Myers B; Ambekar A; Strathdee SA;
Lancet; 2010 Mar; 375(9719):1014-28. PubMed ID: 20189638
[TBL] [Abstract][Full Text] [Related]
3. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
[TBL] [Abstract][Full Text] [Related]
4. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
[TBL] [Abstract][Full Text] [Related]
5. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S
Lancet Glob Health; 2017 Dec; 5(12):e1192-e1207. PubMed ID: 29074409
[TBL] [Abstract][Full Text] [Related]
6. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries.
Degenhardt L; Mathers BM; Wirtz AL; Wolfe D; Kamarulzaman A; Carrieri MP; Strathdee SA; Malinowska-Sempruch K; Kazatchkine M; Beyrer C
Int J Drug Policy; 2014 Jan; 25(1):53-60. PubMed ID: 24113623
[TBL] [Abstract][Full Text] [Related]
7. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Addiction; 2018 Mar; 113(3):545-563. PubMed ID: 28891267
[TBL] [Abstract][Full Text] [Related]
8. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.
MacArthur GJ; van Velzen E; Palmateer N; Kimber J; Pharris A; Hope V; Taylor A; Roy K; Aspinall E; Goldberg D; Rhodes T; Hedrich D; Salminen M; Hickman M; Hutchinson SJ
Int J Drug Policy; 2014 Jan; 25(1):34-52. PubMed ID: 23973009
[TBL] [Abstract][Full Text] [Related]
9. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB
J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335
[TBL] [Abstract][Full Text] [Related]
10. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
[TBL] [Abstract][Full Text] [Related]
11. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.
Vickerman P; Martin N; Turner K; Hickman M
Addiction; 2012 Nov; 107(11):1984-95. PubMed ID: 22564041
[TBL] [Abstract][Full Text] [Related]
12. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.
Stone J; Fraser H; Young AM; Havens JR; Vickerman P
Int J Drug Policy; 2021 Feb; 88():102707. PubMed ID: 32151496
[TBL] [Abstract][Full Text] [Related]
13. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review.
Colledge-Frisby S; Ottaviano S; Webb P; Grebely J; Wheeler A; Cunningham EB; Hajarizadeh B; Leung J; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Degenhardt L
Lancet Glob Health; 2023 May; 11(5):e673-e683. PubMed ID: 36996860
[TBL] [Abstract][Full Text] [Related]
14. Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review.
Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham E; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran LT; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenström A; Degenhardt L; Grebely J
Lancet Glob Health; 2023 Dec; 11(12):e1885-e1898. PubMed ID: 37973339
[TBL] [Abstract][Full Text] [Related]
15. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
[TBL] [Abstract][Full Text] [Related]
16. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania.
Fraser H; Stone J; Wisse E; Sambu V; Mfisi P; Duran IJ; Soriano MA; Walker JG; Makere N; Luhmann N; Kafura W; Nouvellet M; Ragi A; Mundia B; Vickerman P
J Int AIDS Soc; 2021 Oct; 24(10):e25817. PubMed ID: 34661964
[TBL] [Abstract][Full Text] [Related]
17. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of high-risk drug use and coverage of opioid substitution treatment and needle and syringe programs in Lithuania in 2015-2016: A multi-method estimation study.
Thanki D; Mravčík V; Běláčková V; Mačiulytė D; Zábranský T; Širvinskienė A; Subata E; Lorenzo-Ortega R
J Subst Abuse Treat; 2021 Mar; 122():108229. PubMed ID: 33509418
[TBL] [Abstract][Full Text] [Related]
19. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
[TBL] [Abstract][Full Text] [Related]
20. High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review.
Des Jarlais DC; Feelemyer JP; Modi SN; Abdul-Quader A; Hagan H
BMC Public Health; 2013 Jan; 13():53. PubMed ID: 23332005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
